podcasts

Accio reached 10 million MAU in March, and Alibaba says it cut procurement communication from about one week to one day. My read is that this is not a “better B2B chatbot” story. It is Alibaba trying to turn the messiest human layer in cross-border trade into an agent workflow it can route, score, and eventually monetize. If that works, the asset is not app engagement. The asset is control over how products get defined, suppliers get surfaced, and deals get pushed toward closing. The important part in the interview is Zhang Kuo’s framing of A2A. He is not talking about one buyer using one assistant. He is talking about buyer agents, seller agents, and platform processes all being rewritten together. That is a much heavier claim than adding a copilot to SaaS. The workflow described is concrete enough to take seriously: product research, design-pack generation, multilingual communication, supplier screening, then transaction-side progression. That tells you Alibaba cares about the task unit, not the chat unit. Whoever owns the task chain sits much closer to the eventual order. This lines up with a pattern we have seen across the last year. Most agent products hit one of two walls. They either generate content well but never enter the system of record, or they can call tools but lack a dense enough operational setting and enough historical data to improve. Alibaba has both. It already has supply-side inventory, seller history, and transaction rails through Alibaba.com. That makes this a different game from general-purpose agent platforms. OpenAI and Anthropic have stronger generic interfaces and frontier models. Alibaba has the advantage of owning the place where the commercial task actually happens. I’ve thought for a while that agent adoption would land first in workflows that already look like state machines: tickets, claims, procurement, approvals, logistics exceptions. Cross-border sourcing fits that shape almost perfectly. I still have two big reservations. First, 10 million MAU sounds great, but the interview does not disclose retention, paid conversion, buyer-vs-seller mix, or downstream GMV impact. For a B2B product, MAU is not the decisive metric. A procurement agent has to prove that repeat sourcing gets better, inquiry-to-order conversion rises, sample cycles shrink, or dispute rates fall. “Communication time fell to one-fifth” only proves the front of the funnel got faster. It does not prove trade quality improved. Platform companies love usage numbers because they hide whether the economic layer actually got better. Second, I only buy half of the A2A narrative. Buyer and seller agents will absolutely wipe out a lot of low-value coordination work, especially across languages, time zones, and vague specs. But the most expensive failures in B2B sourcing usually happen after the conversation looks fine: factory verification, quality control, delivery reliability, chargebacks, accountability. The interview says AI can generate a technical design pack. Good. A design pack is not the same thing as supplier trustworthiness. The question I wanted answered is simple: when Accio ranks 10 suppliers, what signals dominate the ranking? Historic on-time delivery? refund rates? reorder rates? offline audits? complaint history? If that weighting is opaque, Alibaba stops being a neutral marketplace and starts acting like a procurement manager. That creates a real liability and governance issue. There is a useful comparison here. Amazon Business spent years digitizing enterprise procurement around catalog, pricing, accounts, and fulfillment. Alibaba is pushing earlier into the chain: what to make, how to spec it, who to talk to. That is a bigger ambition. It is also riskier. A closer AI-era comparison is Shopify Sidekick, which helps merchants operate stores better. Sidekick still sits far from cross-border supply-chain decisions. Alibaba’s edge is that the workflow is native to its platform. Its weakness is that it now has to show it is not simply turning traffic allocation and supplier discovery into a black box with an AI label. I also found Zhang’s comments on Claude Cowork and open agents revealing. Alibaba does not want the most open general agent. It wants agents that are verifiable, controllable, and billable inside high-value workflows. That is a pragmatic choice. B2B is not won by the flashiest demo. It is won by keeping error cost low. His example was good: if an 18-step process runs at 90% accuracy per step, the final output is basically unusable. That is more honest than most agent launches this year. Too many products still sell “one-click autonomous execution” and then collapse under error accumulation once they hit real enterprise processes. If Alibaba designs this around human checks at key steps, that is less sexy and more commercially credible. My final pushback is the “one-person company doing global trade” headline. I think that part is overcooked. AI can compress a small team. It can lower the research and communication barrier to sourcing. But global trade has never been blocked only by search and messaging. Tax, compliance, inspections, returns, warehousing, cash flow, and post-sale handling still decide whether a tiny operator survives. The interview does not get into those layers. So I would not buy the solo-entrepreneur slogan yet. I would, however, keep watching Alibaba here because it has the three ingredients most agent startups do not: native workflow, supply density, and transaction closure. Right now the disclosed proof is front-end efficiency. The harder proof is whether the full trade stack gets better, not just faster.

Jensen put Blackwell plus Vera Rubin at at least $1 trillion in cumulative orders by the end of 2027, and my read is simple: this is a supply-chain claim dressed up as a demand claim. The episode compares it with the roughly $600 billion global semiconductor market in 2024, which is a good attention hook, but the comparison blurs the accounting. Nvidia is not talking about GPU revenue alone. The podcast itself frames this as a platform number that includes chips, NVLink, switches, and software. Once the unit shifts from chip to system, the headline expands fast. I read this less as a clean revenue forecast and more as Nvidia setting an anchor for customers, suppliers, and capex markets at the same time. The performance claims need more skepticism than the episode gives them. It cites seven Rubin chips launched at once, NVL72 delivering 10x inference efficiency over Blackwell, cost per token falling to one-tenth, and token per watt improving 35x. Those are big numbers. The body does not disclose the benchmark, model size, precision, batch regime, or whether this is per rack or per cluster. That matters. Nvidia keynotes often mix silicon gains, network gains, software gains, and workload-shape gains into one system-level multiplier. Those gains can still be real, but they are not interchangeable. If I cannot see the test conditions, I do not put those figures straight into a deployment model. The stronger part of the discussion is the bottleneck analysis. CoWoS, HBM4, and power are the right pressure points. In practice, the hardest constraint in large AI clusters has often not been leading-edge wafer supply by itself. It has been advanced packaging, memory, liquid cooling, transformers, switchgear, and utility interconnection showing up as one long chain. The episode says TSMC CoWoS capacity has roughly tripled since 2024. I have not verified that exact ratio line by line, but the direction is right: packaging expanded fast, and AI demand expanded faster. HBM4 is in the same bucket. Micron, Samsung, and SK hynix can all announce progress, but stack yield, thermal behavior, and custom integration do not become trivial because a press release says “mass production.” If Rubin-class systems ramp on the schedule Nvidia wants, packaging and memory cadence still look like the first places where delivery can slip. I also want to push back on one part of the podcast because it is not a small detail. The Groq section appears wrong. The transcript says Nvidia acquired Groq late last year and then shipped an LPU product at GTC. I could not find any basis for an Nvidia acquisition of Groq, because Groq has been an independent company. That matters because it distorts the competitive map. Groq’s pitch is real enough: low-latency, deterministic execution, and reduced data movement for certain decode-heavy inference paths. But that is very different from saying Nvidia folded Groq into its portfolio and now recommends every data center reserve 25% of capacity for it. I do not buy that narrative as stated. The broader context missing from the episode is that Nvidia is no longer selling “training accelerators” as the core story. It is selling token factories. That framing has hardened over the past year because hyperscaler capex has been shifting from pure pretraining toward inference-heavy deployments. OpenAI, Anthropic, Meta, and the cloud vendors have all spent the last year showing how long context, agent loops, tool use, and always-on serving create recurring inference load. Training looks like building the plant. Inference looks like paying the utility bill every day. Jensen’s trillion-dollar line is really a bet that agent-driven token demand becomes durable enough to justify infrastructure on that scale. I still think the demand side is less settled than Nvidia wants investors to believe. Agent usage is rising, but enterprise adoption is not gated by GPUs alone. The drag is integration, permissions, evals, human fallback, and procurement. A lot of today’s token growth can also be offset by caching, model routing, distillation, smaller task-specific models, and custom inference silicon. We already watched one full cycle where stronger models pushed unit economics down fast. Nvidia is trying to maximize token volume while its customers are trying to minimize cost per token. Those two forces coexist. So my bottom-line judgment is this: the trillion-dollar target does not prove unlimited demand. It proves Nvidia wants to turn supply chain control, packaging access, networking, software, and power readiness into one commercial language. That is a strong position while few others can coordinate the full stack. It is less permanent than the keynote suggests. If hyperscaler ASIC programs, AMD, and specialized inference chips keep improving, Nvidia’s edge shifts from “only vendor that can deliver” to “easiest vendor to deliver with.” That is still valuable, but it is a different kind of moat. The episode talks up the peak. The softer spot is not weak demand. It is whether Nvidia can convert demand into shipped systems without delivery cadence and return on capital becoming the first real constraints.

OpenClaw tightened defaults in v3.2, yet the show’s own number tells the story: roughly 250 security advisories means this stack is still being patched in flight. I don’t see this as “just a better local assistant.” I see an execution layer that binds a model to system commands, browser state, third-party Skills, and long-running automation. A chat model failing gives you bad text. An execution layer failing deletes files, clicks through logged-in sessions, or ships secrets upstream. Those are different classes of failure. The risk ladder in the discussion is actually the useful part: readable local files, chat data sent upstream, logged-in browser sessions, malicious links or Skills, and repeated mistakes in scheduled tasks. That maps cleanly onto what the field already learned during the Auto-GPT and plugin wave in 2023. Back then, the issue was never only “the model is wrong.” The issue was that once a model got tools plus untrusted inputs, prompt injection, over-broad actions, and cascading mistakes stopped being academic. A lot of teams quietly pulled agents back toward copilot mode after that. Not because they got timid, but because the safety boundary around execution never caught up. OpenClaw is walking into the same problem with a better product surface and a larger audience, so the failures feel more immediate. I buy the show’s main operational advice: isolation matters more than fine-grained permission tweaking. Those solve different problems. A permission panel answers whether the agent is allowed to do something. Isolation answers what gets destroyed when it does the wrong thing anyway. Give it an old machine, a separate workspace, a segmented network, even root if you must, and the blast radius stays bounded. Put it on your primary work laptop and tell yourself you’ll be careful, and you’re relying on discipline where architecture should be doing the work. Browser state is the most underestimated piece here. The agent does not need your password if it can drive a logged-in Gmail, GitHub, exchange, or cloud console. Session equals privilege. Privilege equals assets. Security people in crypto learned this the hard way years ago; the weak point is often the endpoint and the session, not the cryptography. I do push back on one framing in the episode: that the main problem is user FOMO and over-granting permissions. That is only half true. The other half is product architecture and defaults. If a system needs the user to understand Docker, VMs, Tailscale, loopback-only exposure, and least privilege before it becomes reasonably safe, then it is nowhere near mainstream-safe deployment. The fact that v3.2 only recently tightened defaults says earlier design choices leaned hard toward capability first. Capability first is fine if you stop marketing it with a mass-user ease narrative. Security does not get patched in through user education alone. Safe defaults, narrow scopes, audit logs, rollback, reproducible sandboxes, and strong session isolation are the foundation. The transcript says fixes are frequent, but it does not disclose issue severity mix, exploit prevalence, or whether any independent audit exists. Without that, “they patch fast” does not equal “this is stable.” There’s another tension the show surfaces without fully naming it: “don’t feed it external inputs” is good advice, but external inputs are exactly where the agent’s value comes from. No links, no Skills, no network services, no automation, and you’ve reduced the product back toward a premium chat window. The second it touches the world, the world can push back through poisoned content, malicious pages, bad packages, or simply ambiguous instructions. That means the winners in this category are unlikely to be the teams with the largest Skill store first. They’ll be the teams that build a thick untrusted-input handling layer first: link sanitization, scoped one-time tokens, browser containerization, action previews, multi-step approvals, execution logs, and rollback. Web2 plugins and crypto wallets both already paid tuition on “expand the ecosystem first, govern it later.” I don’t think the market gets to pretend this lesson is new. One more thing: 250 advisories is not automatically a badge of transparency. It can also be evidence of a very large attack surface that forces constant disclosure. Both can be true at once. The show mentions releases every one or two days, even hour-level iteration around the ecosystem. That sounds great from a product velocity angle. It looks shakier from a security-baseline angle. Traditional software can survive rapid updates when tests are deep, privilege models are stable, and interfaces are controlled. Agent frameworks are weak on exactly those three areas. Many patches also add new capabilities, and new capabilities widen the surface again. So this is not a clean linear march toward safety; it’s a moving target. My read on the episode is that it’s bigger than OpenClaw. It describes the core flaw of high-permission agents as a category. Model quality is improving faster than system-boundary design. Today the visible failures are file deletion and session misuse. Tomorrow the ugly incidents will sit in cloud APIs, enterprise knowledge sync, and long-running automated workflows. If you treat this like a helpful digital pet, you’ll get burned. If you treat it like an untrusted contractor with machine speed, isolate it, log it, scope it, and assume it will eventually do the wrong thing, your posture is finally realistic.

Mass General primary care doctors work 61.8 hours a week while seeing only 15-25 patients a day, and that number already tells you where the market is. In US healthcare, the first AI companies to make real money will not be the teams with the most impressive diagnostic demos. They will be the ones that can eat paperwork, prior auth, coding, compliance, and system integration. I broadly buy the episode’s frame, but I’m less convinced by some of the capital-market storytelling around it, especially OpenEvidence at roughly $100 million ARR and a $12 billion valuation. That multiple does not explain itself. The transcript does not disclose retention, customer mix, gross margin, or distribution costs. The most useful fact in this piece is not that OpenAI launched ChatGPT Health or that Anthropic launched Claude for Healthcare. It is that US clinicians still burn huge chunks of their week on insurance, documentation, coding, and claims workflows. The actual buyers here are not “doctors who like AI.” They are hospitals, clinics, payers, and revenue-cycle operators getting crushed by administrative cost. If a product cuts denial rates by a few points, shortens prior-auth turnaround by days, or saves clinicians 20-30% of documentation time, budget appears fast. The episode gives one mechanism that matters: only about 10% of denied claims go to appeal, yet about 80% of appealed denials are overturned. That strongly suggests a lot of waste comes from process and coding failure, not from bad medicine. AI is naturally useful there because these tasks are text-heavy, repetitive, rule-bound, and backed by historical examples. I’ve always thought healthcare AI gets distorted when people hear “healthcare” and immediately think “diagnosis model.” Over the last year, a lot of the faster-moving money in the US has gone into ambient scribing, prior authorization, RCM, patient messaging, and clinician copilots. Companies like Abridge, Nabla, and Suki have gained traction less because they beat frontier models on medical QA and more because they fit into Epic or other clinical workflows, clear compliance reviews, and save clicks in practice. The episode’s point that Claude for Healthcare leans toward infrastructure is more convincing than any “who understands medicine better” framing. Model capability is commoditizing faster than integration, auditability, and liability handling. There’s an important layer the episode only touches indirectly. In US healthcare IT, the moat has long sat in distribution and embed, not raw model quality. Once an EHR becomes the default workspace, every outside vendor is fighting for a handful of insertion points: note generation, coding suggestions, order assistance, patient communication, evidence retrieval. If you cannot sit inside clinician workflow, a great answer is still just a demo. I could not find key operating details in this transcript about ChatGPT Health: whether it ships with HIPAA BAAs, enterprise logging, private deployment options, or direct integration into systems like Epic. The title gives a product name; the transcript does not give the conditions that determine adoption. Without that, “who can win” remains premature. The Eli Lilly and Nvidia collaboration, framed at around $1 billion, is obviously headline-friendly. I still push back on how much signal people draw from those announcements. First, the transcript does not break down what that $1 billion actually is: cash contract, compute commitment, joint lab budget, investment pool, or multi-year strategic ceiling. Those are very different things. Second, pharma-Nvidia collaboration does not automatically translate into hospital software demand. Drug discovery, clinical trial tooling, RWE pipelines, molecular simulation, and provider-side workflow automation live in different budget buckets and have different buying committees. “Healthcare AI” often gets treated like one market. It is not. Mixing pharma, hospitals, payers, and consumer health leads people to overstate synergy and understate go-to-market difficulty. The section on federated learning and data control is where the episode feels grounded. I’ve heard the “30% of the world’s data is healthcare data” line many times, and those macro stats often float around with inconsistent definitions, so I’m not going to certify that number. But one thing is clear: if raw records, imaging, and claims data cannot move freely, then federated compute, on-prem deployment, audit logs, and fine-grained access control are not side features. They are the product. A lot of general-purpose model vendors have moved slower in healthcare not because the model is weak, but because providers ask the same four questions first: where does the data sit, who can access it, who is liable when something goes wrong, and can it write back into existing systems. Model quality is only one of those four. Can startups win here? Yes, but the win condition looks nothing like consumer AI. This is not a market where you chase DAU first and think about monetization later. A startup usually has to nail one narrow workflow first — ED notes, oncology prior auth, radiology draft reports, coding review — with explicit pricing and measurable ROI, then expand inside the same institution. If a company like OpenEvidence ends up justifying its valuation, I doubt the reason will be the fantasy of an “AI doctor.” More likely it will be that evidence retrieval becomes a default clinician action and earns a high-frequency slot in workflow. I’m still not sold on a $12 billion price tag because the transcript gives none of the numbers I’d want: net retention, implementation burden, gross margins, customer concentration, or whether revenue comes from providers, pharma, or some distribution deal. Honestly, the episode is strongest when it puts HIPAA, data custody, and system integration ahead of model scores. Many teams are still telling benchmark stories while procurement teams are asking about SOC 2, BAAs, PHI boundaries, write-back interfaces, and liability assignment. Models will keep improving. The first healthcare AI category leaders will be the vendors that absorb operational risk and fit into enterprise reality. The transcript appears incomplete, so I’m not going to call winners from this material alone. My take is simpler: in 2026, US healthcare AI is already less about who sounds most like a doctor and more about who behaves most like software that a hospital can actually approve and deploy.

Clawdbot reached 146k GitHub stars by Feb. 2, and that spike tells me users are buying “relationship feel” before they’re buying a better model score. The podcast keeps circling the same stack: Claude, long-term memory, IM as the interface, and heartbeat-style proactive triggers. None of those pieces are novel on their own. Claude Code, Manus, memory-layer startups, and companion products have been shipping adjacent ideas for a while. What OpenClaw did well was compress those parts into one loop that feels socially native. People stopped feeling like they were opening another chatbot tab and started feeling like the agent was already there. That distinction matters more than the hosts admit. The category shift here is from task mode to standby mode. Web chat is explicit invocation: open window, type prompt, wait. IM plus proactive nudges changes the cadence. The agent occupies spare attention. It keeps state across the day. It can watch something low-frequency but persistent, then surface action at the right moment. The examples in the episode are basic but revealing: remind me before food expires, monitor a server for a day, turn a test result into a blog post in my tone. These are not frontier-reasoning demos. They are frequency demos. If an agent can legitimately interrupt you 5 to 20 times a day with useful context, it will outrun a stronger tool that only wakes up when summoned. That’s why I’m skeptical of the “Mac mini rush” framing in the title. The body gives no sales numbers, no inventory context, no retail channel evidence, no time window. So we can’t tell whether this was actual hardware demand, a temporary enthusiast run, or just social amplification around the idea of an “Agent computer.” I wouldn’t translate feed hype into a hardware cycle yet. We already saw an AI PC hype wave in 2024, and most real deployments ended up as cloud inference plus a thin local daemon, not a second dedicated machine sitting on everyone’s desk. The better outside comparison is product control. Manus got attention because it said, “delegate the work to me.” Claude Code took off because it said, “let me drive the computer.” Clawdbot is landing because it says, “let me sit in your daily channel.” That is a more aggressive move than it sounds. Giving a model terminal access or browser control still feels exceptional. Giving it WhatsApp, WeChat, or Feishu makes it feel routine first and risky later. That is smart distribution. It borrows an existing habit instead of asking users to form a new one. I still have two major doubts. First is security. The article mentions MoltBook exposing sensitive information and also says many of the supposed 1.5 million AIs were actually humans role-playing. Those are huge claims, and the body doesn’t provide technical disclosure strong enough to evaluate either. Once you wire together personal history, IM, reminders, and server actions, the fragile layer is rarely model quality. It’s permissioning, logging, key management, plugin isolation, and auditability. Every major agent demo in the last year has looked clean at demo time and messy at identity time. Running a workflow is easy. Safely hosting a persona is hard. Second is cost. The podcast says the server bill became astronomical, but it doesn’t break down token spend, message polling, tool invocation, storage, or bandwidth. That omission matters. Proactive agents don’t usually die on DAU; they die on idle burn. Heartbeat loops are seductive because they create presence, but presence is expensive if the architecture is naïve. Nvidia and hyperscalers love this pattern because it expands always-on inference demand. Product teams should be less romantic. A proactive agent that checks too often or remembers too much becomes a margin leak very quickly. One thing I do buy is the way this product makes “memory” legible to normal users. Last year a lot of teams sold memory as infrastructure: compression, retrieval, profile layers, long-term state stores. Developers understood it. Most users did not care. OpenClaw turns memory into behavior that shows up in your messages unprompted. That makes the value obvious. It reminds me of the moment RAG stopped being a technical term and started meaning “it can answer from my docs.” Same underlying ingredients, better manifestation. I also don’t buy the idea that breakout traction equals a moat. Fast GitHub stars mean developer FOMO and strong open-source distribution. They do not mean retention, conversion, or low incident rates. The fact that the project reportedly went from Clawdbot to Moltbot to OpenClaw within a week already tells you the product is moving faster than the org, brand, and legal layer. Early on, that speed helps. Once the system touches IM, memory, identity, and autonomous execution, those “boring” layers stop being back-office issues and become core product quality. My read is that this won’t send the market straight to “everyone buys an Agent computer.” It will push the market toward “everyone expects a resident agent entry point.” That entry point may live in IM, email, or the system menu bar. It does not need dedicated hardware. The teams that win from here won’t be the ones with the flashiest Claude wrapper. They’ll be the ones that make permissions sane, memory decay intentional, and proactive scheduling cheap enough to survive contact with real usage.

My read on the CES humanoid wave is simple: exhibitor count has outrun commercial proof. The official figure cited in the episode is 38 humanoid exhibitors, 21 of them Chinese. Boston Dynamics then adds a clean narrative on top of that: Atlas deliveries in 2026, annual capacity of 30,000 by 2028. Big numbers, strong stagecraft. But the most grounded line in the discussion is still the blunt one: scale plans are not deployment. I buy that. In warehousing, material handling, and inspection, buyers optimize for ROI, uptime, and safety, not for a robot matching the human silhouette. If a wheeled base with two arms delivers 95% of the task at half the cost, procurement will not reward the extra degrees of freedom in legs. That is not a timid view; it is how robotics has usually commercialized. Warehouse automation already showed the pattern. Amazon’s Kiva move worked because it isolated mobility first, then layered in orchestration and other capabilities. Over the last year, Agility’s Digit, Figure’s factory demos, and 1X’s home story all pushed the opposite thesis: start with a general human form and let software catch up. I’ve never fully bought that sequencing. The first wall is not model intelligence alone. It is systems engineering: battery life, maintenance intervals, grasp success rates, fall recovery, remote teleoperation ratios, and how often a human operator has to step in. If one of those metrics is ugly, the sales deck stops mattering. That is why the episode’s praise for systems like Sunday’s wheeled base plus manipulation stack rings true to me. It removes the hardest balance problem and concentrates engineering on manipulation. In robotics, winning often means solving fewer hard problems, not solving the most glamorous one. I’m also skeptical of the Boston Dynamics 30,000-capacity claim for 2028. Not because building 30,000 units is impossible in the abstract, but because demand at that level is the real question. Tesla Optimus already taught the sector this pattern: targets start huge, then collide with manufacturing cadence, supply-chain yield, safety validation, and the boring question of whether the task should be done by this form factor at all. The episode says Tesla’s 2025 target was cut in half after a leadership change; I haven’t verified that exact figure. Still, the broader pattern is familiar. Humanoid roadmaps expand faster than deployed fleets. There is another layer here that the discussion gets right: the current humanoid boom is unusually capital-friendly. In Shenzhen, a company can assemble a humanoid demo from a mature supply chain, brand it, tune a walking routine, and get on a CES floor with far less technical risk than training a frontier model that has to survive benchmarks. That has consequences. Over the next year, “fundable” will stay ahead of “deployable” for many humanoid startups. Expect more unveilings, more pilot announcements, and more memoranda of understanding. What remains missing, again and again, is the operating data: unit economics, service burden, intervention rate, task success distribution, and failure severity. If those numbers are absent, the story is still pre-product no matter how polished the robot looks. I’m not anti-humanoid. Human environments are built for human geometry: stairs, handles, shelf heights, tool interfaces. Long term, a general-purpose humanoid still makes conceptual sense. My pushback is about ordering. For factories and warehouses, forcing bipedal locomotion into the stack this early looks like adding the most expensive and fragile subsystem before the business case is there. Get wheeled mobile manipulation working across a set of repetitive, high-value tasks first, then climb toward broader embodiment. That feels like engineering, not theater. CES this year showed that the industry is getting very good at presenting robots that look human. It still has not shown enough numbers to prove they beat the cheaper alternatives where customers already spend money.